gleevec.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Sitemap: http://us.gleevec.com/sitemap.xml Disallow: | ||
Meta Tags
| Title | GLEEVEC® (imatinib mesylate) | KIT + GIST & Ph+ |
| Description | Prescribing Learn about GLEEVEC, an approved treatment for KIT + GIST and Philadelphia chromosome-positive chronic myeloid leukemia. See full Prescribing & Safety |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 217.114.85.100 |
| Location | Sweden |
Related Websites
| Site | Rank |
More to Explore
gleevec.com Valuation
|
US$28,332,775
Last updated: 2023-05-05 23:56:34
gleevec.com has Semrush global rank of 373,571. gleevec.com has an estimated worth of US$ 28,332,775, based on its estimated Ads revenue. gleevec.com receives approximately 3,269,167 unique visitors each day. Its web server is located in Sweden, with IP address 217.114.85.100. According to SiteAdvisor, gleevec.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$28,332,775 |
| Daily Ads Revenue | US$26,154 |
| Monthly Ads Revenue | US$784,600 |
| Yearly Ads Revenue | US$9,415,200 |
| Daily Unique Visitors | 217,945 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| gleevec.com. | A | 7198 | IP: 217.114.85.100 |
| gleevec.com. | NS | 1800 | NS Record: dns2.novartis.com. |
| gleevec.com. | NS | 1800 | NS Record: a9-65.akam.net. |
| gleevec.com. | NS | 1800 | NS Record: a7-64.akam.net. |
| gleevec.com. | NS | 1800 | NS Record: dns3.novartis.com. |
| gleevec.com. | NS | 1800 | NS Record: a1-254.akam.net. |
| gleevec.com. | NS | 1800 | NS Record: dns1.novartis.com. |
| gleevec.com. | NS | 1800 | NS Record: a2-66.akam.net. |
| gleevec.com. | NS | 1800 | NS Record: a24-65.akam.net. |
| gleevec.com. | NS | 1800 | NS Record: dns4.novartis.com. |
| gleevec.com. | NS | 1800 | NS Record: a28-67.akam.net. |
| gleevec.com. | TXT | 86400 | TXT Record: _globalsign-domain-verification=tVdVCs40EtFcHbtfINtE9aWKQFRQ7ENxR7Sr2L4_Vl |
| gleevec.com. | TXT | 86400 | TXT Record: c8389359-5859-495b-ba68-28437c4303d6 |
| gleevec.com. | TXT | 86400 | TXT Record: facebook-domain-verification=2vc6tn3x6odin57kzgtjbwr4gov0po |
HtmlToTextCheckTime:2023-05-05 23:56:34
| For US residents only. Prescribing Information Prescribing Information Important Safety Information < Back To Site Prescribing Information Important Safety Information Who Should NOT Take GLEEVEC Women who are or could be pregnant. Harm to the unborn child can occur when administered to a pregnant woman. Therefore, women should not become pregnant and should be advis ... See More Approved Use GLEEVEC ® (imatinib mesylate) is available only by prescription. GLEEVEC tablets are indicated for: Newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase Patients with Ph+ CML in blast crisis (BC ... See More Read Full Important Safety Information and Approved Use Back To Site GLEEVEC ® (imatinib mesylate) tablets have delivered efficacy and safety data backed by almost two decades of clinical use. 1 First approved by the FDA in 2001 1 , the figures speak for themselves. Over 15,000 published articles 2 Over |
HTTP Headers
HTTP/1.0 301 Moved Permanently Location: https://www.gleevec.com/ Server: BigIP Connection: Keep-Alive Content-Length: 0 HTTP/2 301 date: Tue, 26 Oct 2021 18:18:00 GMT content-type: text/html; charset=utf-8 content-length: 144 cache-control: private location: https://www.us.gleevec.com/ set-cookie: ASP.NET_SessionId=zwshsjisnrd50q2akzqyr45p; path=/; secure; HttpOnly; SameSite=Lax request-context: appId=cid-v1:fbded6d8-2f5c-4cb0-adf7-2ae9d814644f access-control-expose-headers: Request-Context x-xss-protection: 1; mode=block x-content-type-options: nosniff strict-transport-security: max-age=31536000; includeSubDomains x-frame-options: SAMEORIGIN set-cookie: ARRAffinity=7b65e78aa202bf281b88a5638721aa4f837c46d0fd75afabdef0cb2870a44461;Path=/;HttpOnly;Secure;Domain=www.gleevec.com set-cookie: ARRAffinitySameSite=7b65e78aa202bf281b88a5638721aa4f837c46d0fd75afabdef0cb2870a44461;Path=/;HttpOnly;SameSite=None;Secure;Domain=www.gleevec.com cf-cache-status: DYNAMIC expect-ct: max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct" server: cloudflare cf-ray: 6a45af45be8628fb-ORD HTTP/2 200 date: Tue, 26 Oct 2021 18:18:00 GMT content-type: text/html; charset=utf-8 cache-control: private vary: Accept-Encoding set-cookie: ASP.NET_SessionId=gxewsrs0wpjoi5qdmnox24xf; path=/; secure; HttpOnly; SameSite=Lax set-cookie: ASP.NET_SessionId=gxewsrs0wpjoi5qdmnox24xf; path=/; secure; HttpOnly; SameSite=Lax set-cookie: __RequestVerificationToken=PSKvrOZhPQpjd3pHTxFvnBGfh2sMcXExpC_q0nBGAs_I-4z7cOF9vHOVZooTYv9cCZJ0xt3wo7_y6K8738c6WsRXOQ8QG0iQkJXDBFYE9kQ1; path=/; secure; HttpOnly content-security-policy: default-src 'self' 'unsafe-inline' 'unsafe-eval' fonts.googleapis.com fonts.gstatic.com www.googletagmanager.com www.google-analytics.com unpkg.com *.msecnd.net api.fouanalytics.com *.episerver.net *.b2c.com:444 *.b2c.com dc.services.visualstudio.com www.google.com *.doubleclick.net *.kaltura.com novartispharma.hb.omtrdc.net dpm.demdex.net analytics.google.com blob: novartispharma.sc.omtrdc.net bat.bing.com request-context: appId=cid-v1:fbded6d8-2f5c-4cb0-adf7-2ae9d814644f access-control-expose-headers: Request-Context x-xss-protection: 1; mode=block x-content-type-options: nosniff strict-transport-security: max-age=31536000; includeSubDomains x-frame-options: SAMEORIGIN set-cookie: ARRAffinity=600cad8478501eec864f23c43de2cbc13665e4a00d62bae11875281995134fd3;Path=/;HttpOnly;Secure;Domain=www.us.gleevec.com set-cookie: ARRAffinitySameSite=600cad8478501eec864f23c43de2cbc13665e4a00d62bae11875281995134fd3;Path=/;HttpOnly;SameSite=None;Secure;Domain=www.us.gleevec.com cf-cache-status: DYNAMIC expect-ct: max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct" server: cloudflare cf-ray: 6a45af488ac56350-ORD |
gleevec.com Whois Information
Domain Name: GLEEVEC.COM Registry Domain ID: 68915957_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2021-03-05T10:04:48Z Creation Date: 2001-04-06T16:39:41Z Registry Expiry Date: 2023-04-06T16:39:41Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Domain Status: serverDeleteProhibited https://icann.org/epp#serverDeleteProhibited Domain Status: serverTransferProhibited https://icann.org/epp#serverTransferProhibited Domain Status: serverUpdateProhibited https://icann.org/epp#serverUpdateProhibited Name Server: A1-254.AKAM.NET Name Server: A2-66.AKAM.NET Name Server: A24-65.AKAM.NET Name Server: A28-67.AKAM.NET Name Server: A7-64.AKAM.NET Name Server: A9-65.AKAM.NET Name Server: DNS1.NOVARTIS.COM Name Server: DNS2.NOVARTIS.COM Name Server: DNS3.NOVARTIS.COM Name Server: DNS4.NOVARTIS.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-14T17:47:55Z <<< |